← All trials
NCT05125081
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- May 30, 2023
- Completion date
- Oct 30, 2023
- First posted
- Nov 18, 2021
- Last posted
- Nov 29, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiao Tong UniversityLead sponsor
- Jiao Tong UniversityReponsible party - principal investigator
- Jiao Tong UniversityStudy director
- Jiao Tong UniversityOverall official - principal investigator
- Shanghai University of Traditional Chinese MedicineCollaborator
- Shanghai Yueyang Integrated Medicine HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.